Content about Chattem

February 4, 2014

Sanofi and its U.S. consumer healthcare division Chattem on Tuesday announced that Nasacort Allergy 24HR Nasal Spray is now available over the counter in the United States to relieve seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older.

BRIDGEWATER, N.J. — Sanofi and its U.S. consumer healthcare division Chattem on Tuesday announced that Nasacort Allergy 24HR Nasal Spray is now available over the counter in the United States to relieve seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older.  

December 26, 2013

Heading into 2014, there are a number of growth drivers across the digestives space.

Heading into 2014, there are a number of growth drivers across the digestives space. There’s the possible switch of Nexium into over-the-counter aisles, brands like Imodium are experiencing a resurgence with their return to the shelves, and Chattem is bringing the venerable Rolaids brand back into the digestives fold.

October 18, 2013

CCA Industries, a marketer and distributor of such health and beauty products as Nutra Nail nail care treatments and Gel Perfect gel color, has appointed Richard Kornhauser as CEO and president, effective immediately.

EAST RUTHERFORD, N.J. — CCA Industries, a marketer and distributor of such health and beauty products as Nutra Nail nail care treatments and Gel Perfect gel color, has appointed Richard Kornhauser as CEO and president, effective immediately.

October 18, 2013

Chattem recently announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies. And that means by spring 2014, there will be another allergy powerhouse alongside Allegra, Claritin and Zyrtec.

Chattem recently announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies. And that means by spring 2014, there will be another allergy powerhouse alongside Allegra, Claritin and Zyrtec. 

October 14, 2013

Allergy sufferers will have a new treatment option available to them by the spring allergy season. Sanofi on Friday announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older.

PARIS — Allergy sufferers will have a new treatment option available to them by the spring allergy season. Sanofi on Friday announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older. 

Nasacort is the first and only nasal corticosteroid to be available without a prescription and will be marketed by Sanofi's consumer healthcare division, Chattem.

September 16, 2013

Sanofi US and its consumer health business Chattem on Monday unveiled plans to re-introduce the iconic Rolaids heartburn-relief brand to the U.S. market.

PARIS — Sanofi US and its consumer health business Chattem on Monday unveiled plans to re-introduce the iconic Rolaids heartburn-relief brand to the U.S. market. The brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.  

September 10, 2013

This year's spring allergy season has been characterized by a late start. "The allergy season was very weak in February and March, and even the beginning of April [was] very weak," William Peters, CFO and VP finance for Hi-Tech Pharmacal, told analysts in July.

This year's spring allergy season has been characterized by a late start. "The allergy season was very weak in February and March, and even the beginning of April [was] very weak," William Peters, CFO and VP finance for Hi-Tech Pharmacal, told analysts in July. "June was more consistent with the previous year," he added.

September 10, 2013

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

August 12, 2013

Innovation. It’s what everybody in the Sands Expo Center is looking for — that kind of traffic-driving innovation that breaks the mold and generates $100 million to $200 million in first-year sales.
But what does innovation look like?

CHICAGO — Innovation. It’s what everybody in the Sands Expo Center is looking for — that kind of traffic-driving innovation that breaks the mold and generates $100 million to $200 million in first-year sales. But what does innovation look like?

August 8, 2013

Despite significant challenges coming from private label, Procter & Gamble is still attempting to innovate the No. 1 brand in all of digestives — Prilosec OTC.

Despite significant challenges coming from private label, Procter & Gamble is still attempting to innovate the No. 1 brand in all of digestives — Prilosec OTC. The company launched a wildberry-flavored Prilosec OTC earlier this year, not to be chewed, but to improve the experience in taking a Prilosec OTC tablet versus an unflavored, generic equivalent.

August 8, 2013

The coming cough-cold season is difficult to project. On one hand, this year's cough-cold incidence will be going against very strong illness rate numbers from last year. In addition, with both McNeil Consumer and Novartis Consumer supporting the relaunch of a number of cough-cold products, the category is expected to be very promotional this season, a factor that could squeeze margins.

DSN estimates that annualized sales of cold and allergy products through mid-June were up 7.9%, representing almost $570 million in incremental dollars.

What are the chances of that happening again?

August 1, 2013

Sanofi Wednesday evening announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee voted 10-6 in favor of its switch application of the nasal corticosteroid Nasacort AQ. Two committee members abstained.

SILVER SPRING, Md. — Sanofi Wednesday evening announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee voted 10-6 in favor of its switch application of the nasal corticosteroid Nasacort AQ. Two committee members abstained. 

May 30, 2013

Chattem recently catapulted its Allegra brand into the anti-itch space with the launch of Allegra Anti-Itch Intensive Relief Cream.

BRIDGEWATER, N.J. — Chattem recently catapulted its Allegra brand into the anti-itch space with the launch of Allegra Anti-Itch Intensive Relief Cream.

Formulated with a skin protectant and topical analgesic, the brand extension will certainly turn a few heads as the Allegra brand name now will be featured in the first-aid section. Anti-itch as a category generated $481.6 million in sales for the 52 weeks ended April 21, climbing 1.8%, according to IRI data across total multi-outlets.

April 11, 2013

Chattem announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

BRIDGEWATER, N.J. — Chattem on Thursday announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

"We identified an opportunity in the topical anti-itch category and leveraged our experience with Allegra Allergy to introduce a new product for common skin irritations that not only helps stop the itch but also provides a moisturizing benefit," stated John Stroud, EVP marketing, Chattem. 

April 10, 2013

Chattem introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator.

CHATTANOOGA, Tenn. — Chattem on Tuesday introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator. 

"The innovative packaging is the first of its kind for poison ivy relief," stated Liz Roques, assistant brand manager at Chattem. "The individual Snapplicators include a single treatment so consumers don't have to touch the affected area."

April 3, 2013

Basketball All-Star Lisa Leslie and Chattem created the "Allegra Outdoor Challenge," a series of workout tips to help inspire people to stay active outdoors during spring allergy season.

BRIDGEWATER, N.J. — Basketball All-Star Lisa Leslie and Chattem last week created the "Allegra Outdoor Challenge," a series of workout tips to help inspire people to stay active outdoors during spring allergy season.  

Beginning in April, Allegra's Facebook page will highlight photos and tips from Leslie detailing ways families can take the "Allegra Outdoor Challenge" and escape allergy madness this spring. 

February 11, 2013

Sun & Skin Care Research announced that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

COCOA, Fla. — Sun & Skin Care Research announced on Monday that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

February 8, 2013

During a quarterly conference call Thursday, Sanofi president global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

PARIS — During a quarterly conference call Thursday, Sanofi president of global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

"We plan to relaunch the product, which has been absent of the American markets for production problems on the side of J&J," he told analysts. "We intend to launch the product by the end of 2013, which will further accelerate the performance of Chattem in the United States."

January 7, 2013

Sanofi announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

PARIS — Sanofi on Monday announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

January 2, 2013

Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

SAN DIEGO — Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

September 27, 2011

Global Market Development Center last week named the top 10 scanned items from the 41st annual Global Market Development Center Health Beauty Wellness Marketing Conference.

COLORADO SPRINGS, Colo. — Global Market Development Center last week named the top 10 scanned items from the 41st annual Global Market Development Center Health Beauty Wellness Marketing Conference.

August 16, 2011

The National Advertising Division of the Council of Better Business Bureaus on Tuesday determined Chattem, maker of the Allegra allergy relief medication, provided a reasonable basis for the claim that “only Allegra combines fast, non-drowsy, 24-hour relief.”

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Tuesday determined Chattem, maker of the Allegra allergy relief medication, provided a reasonable basis for the claim that “only Allegra combines fast, non-drowsy, 24-hour relief.”

April 25, 2011

Customers are seeing purple again — reminiscent of another switch that took advantage of the eye-catching color purple. Sanofi-Aventis through its Chattem division in March launched Allegra, the last of the second-generation antihistamines. And purple-powered displays, like this in a Walmart in Lancaster, Pa., dotted the retail pharmacy landscape.


January 25, 2011

Sanofi-Aventis and its U.S. consumer healthcare division Chattem on Tuesday afternoon announced the Food and Drug Administration has approved the Allegra (fexofenadine HCl) family of allergy medication products for over-the-counter use in adults and children 2 years of age and older.

PARIS — Sanofi-Aventis and its U.S. consumer healthcare division Chattem on Tuesday afternoon announced the Food and Drug Administration has approved the Allegra (fexofenadine HCl) family of allergy medication products for over-the-counter use in adults and children 2 years of age and older.

Products will be on store shelves in March, the companies announced.

June 6, 2010

Switch always has been the most significant driver of revenues within the non-prescription aisles, with...